Literature DB >> 423203

Conformational analysis of podophyllotoxin and its congeners. Structure--activity relationship in microtubule assembly.

C F Brewer, J D Loike, S B Horwitz, H Sternlicht, W J Gensler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 423203     DOI： 10.1021/jm00189a001

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  14 in total

1.  Which therapy works better in choroid plexus carcinomas?

Authors:  Su G Berrak; Diane D Liu; Brigitte Wrede; Johannes E Wolff
Journal:  J Neurooncol       Date:  2010-10-26       Impact factor: 4.130

2.  Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.

Authors:  Igor V Magedov; Liliya Frolova; Madhuri Manpadi; Uma devi Bhoga; Hong Tang; Nikolai M Evdokimov; Olivia George; Kathy Hadje Georgiou; Steffen Renner; Matthäus Getlik; Tiffany L Kinnibrugh; Manuel A Fernandes; Severine Van slambrouck; Wim F A Steelant; Charles B Shuster; Snezna Rogelj; Willem A L van Otterlo; Alexander Kornienko
Journal:  J Med Chem       Date:  2011-05-26       Impact factor: 7.446

3.  Synthesis, spectroscopic, and biological studies of novel estolides derived from anticancer active 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate.

Authors:  Jamal Mustafa; Shabana I Khan; Guoyi Ma; Larry A Walker; Ikhlas A Khan
Journal:  Lipids       Date:  2004-07       Impact factor: 1.880

Review 4.  VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.

Authors:  J D Loike
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Molecular modelling evaluation of the cytotoxic activity of podophyllotoxin analogues.

Authors:  Md Afroz Alam; Pradeep Kumar Naik
Journal:  J Comput Aided Mol Des       Date:  2008-12-04       Impact factor: 3.686

6.  Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors:  W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Synthesis and anticancer activities of fatty acid analogs of podophyllotoxin.

Authors:  Jamal Mustafa; Shabana I Khan; Guoyi Ma; Larry A Walker; Ikhlas A Khan
Journal:  Lipids       Date:  2004-02       Impact factor: 1.880

8.  Reengineered epipodophyllotoxin.

Authors:  Igor V Magedov; Nikolai M Evdokimov; Menuka Karki; Amanda S Peretti; Dustin T Lima; Liliya V Frolova; Mary R Reisenauer; Anntherese E Romero; Paul Tongwa; Alexandr Fonari; Jeff Altig; Snezna Rogelj; Mikhail Yu Antipin; Charles B Shuster; Alexander Kornienko
Journal:  Chem Commun (Camb)       Date:  2012-09-17       Impact factor: 6.222

Review 9.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

10.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.